METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT
Clinical trials for METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT explained in plain language.
Never miss a new study
Get alerted when new METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT trials appear
Sign up with your email to follow new studies for METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a pill keep kidney cancer away after surgery?
Disease control OngoingThis phase 3 trial tests whether the drug pazopanib can delay or prevent kidney cancer from coming back in patients who have had all visible tumors removed by surgery. 129 adults with clear cell kidney cancer that had spread are randomly assigned to take either pazopanib or a pla…
Matched conditions: METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to wipe out kidney cancer before surgery
Disease control OngoingThis study tests whether giving two drugs—nivolumab (immunotherapy) and cabozantinib (targeted therapy)—before removing the kidney can make all visible cancer disappear in people with advanced kidney cancer that has spread. About 38 adults with metastatic renal cell carcinoma wil…
Matched conditions: METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT
Phase: PHASE2 • Sponsor: Mark Stein • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Kidney cancer study tests best order of targeted drugs
Disease control OngoingThis study looks at 180 people with kidney cancer that has spread. It compares six different ways to give two drugs (everolimus, bevacizumab, or pazopanib) one after the other. The goal is to see which sequence works best and is safest for controlling the cancer.
Matched conditions: METASTATIC RENAL CELL CARCINOMA WITH CLEAR-CELL COMPONENT
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC